Skip to main content

UM Capital Region Health's Laurel 3-4-5 Alternate Care Site (Laurel ACS) is now operating an outpatient infusion center to administer monoclonal antibody therapies (mAb) as approved by the Federal Drug Administration (FDA) under an Emergency Use Authorization (EUA).

The mAb therapies offered at the Laurel 3-4-5 ACS Infusion Center include:

  • Bamlanivimab (manufactured by Eli Lilly)
  • A combination of casirivimab and imdevimab, administered simultaneously (more widely known as Regeneron, the manufacturer of these treatments)

Hours: The Laurel 3-4-5 ACS Infusion Center is open Monday through Friday, 8 am – 4 pm.

Location: UM Laurel Medical Center, 7300 Van Dusen Road, Laurel, MD 20707

Infusion Center Referral Process

Providers can refer eligible patients to UM Capital Region Health – Laurel 3-4-5 ACS Monoclonal Antibody Infusion Center using the CRISP Monoclonal Antibody eReferral Tool, accessible via the CRISP Unified Landing Page. Please see the Starter Guide for step-by-step instructions on how to refer patients using this form.

Providers without access to CRISP can download a standard MDH fax referral form for Antibody Infusion and fax it to the Infusion Center at (301) 256-9224.

The FDA EUA recommends administering treatment as soon as possible following a positive viral test for SARS-CoV-2 and within 10 days of symptom onset. Given this window, we recommend referrals be made as soon as possible and within seven days of symptom onset to allow time for review and scheduling, if approved, before the patient reaches the 10-day time out for receiving the treatment.

All referrals are being reviewed by a screening RN prior to accepting the patient. The review process may take up to 24-48 hours. If approved, the RN will contact the patient directly to coordinate services as soon as possible.

Please note, we will make every effort to prioritize patients to avoid patient time-outs. There is also a chance that a patient's clinical condition may change in the time between provider referral and patient arrival to the Infusion Center that could deem the patient no longer eligible for treatment. We ask that providers discuss these possibilities with patients to help manage expectations.

Referring providers should reference these Provider Fact Sheets:

Bamlaminivab Provider Fact Sheet

Casirivimab and Imdevimab Provider Fact Sheet

Referring providers should understand that the allocation methodology is based on duration of symptom onset (longest to be prioritized). There is no further risk stratification based on other clinical characteristics at this point.

Which treatment is administered will be chosen based on availability and logistics.

Additionally, there is a chance that a patient's clinical condition may change in the time between referral and arrival to the infusion center. A patient may no longer be eligible. If demand exceeds supply of the drug or the capacity of the COVID Infusion Center, a lottery system will be applied. We urge providers to discuss this with patients and help manage their expectations.

For Patients

Only eligible patients who have been referred by a provider and then approved to receive the treatment will be contacted for scheduling. Please see Laurel ACS COVID Infusion Center Patient Information.

In This Section: